Zevra Therapeutics
ZVRA
120 hedge funds and large institutions have $319M invested in Zevra Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 45 increasing their positions, 29 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
55% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 29
17% more capital invested
Capital invested by funds: $272M → $319M (+$47.4M)
9% more funds holding
Funds holding: 110 → 120 (+10)
0.64% more ownership
Funds ownership: 65.55% → 66.19% (+0.64%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
14% less call options, than puts
Call options by funds: $5.01M | Put options by funds: $5.81M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$6.01M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.46M |
| 3 |
Millennium Management
New York
|
+$4.27M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$3.65M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$4.64M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$4.21M |
| 3 |
JGC
J. Goldman & Co
New York
|
-$3.1M |
| 4 |
Barclays
London,
United Kingdom
|
-$2.68M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.09M |
ZVRA Hedge Fund Activity: Q2 2025 in Review
120 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2025, worth a combined $319M — up 17% from $272M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ZVRA positions and 13 closed out — a net gain of 11 holders — while 45 added to existing stakes and 29 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $6.01M. The largest seller was Readystate Asset Management, cutting an estimated $4.64M.
- 120 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2025, up from 110 in Q1 2025.
- Funds reported $319M of Zevra Therapeutics stock for Q2 2025, up 17% quarter-over-quarter.
- 24 funds opened new Zevra Therapeutics positions in Q2 2025 and 13 closed out, a net change of +11 holders.
- The largest Zevra Therapeutics buyer in Q2 2025 was Rubric Capital Management (New York), an estimated $6.01M added.
- The largest Zevra Therapeutics seller in Q2 2025 was Readystate Asset Management, an estimated $4.64M sold.
Based on aggregated 13F filings for Q2 2025.